NCT04363632 (ONCOVID-19) is a clinical trial in Sars-CoV2, sponsored by Centre Leon Berard.

Who is sponsoring NCT04363632?

NCT04363632 is sponsored by Centre Leon Berard.

What condition does NCT04363632 study?

NCT04363632 studies Sars-CoV2, Cancer.

Is NCT04363632 still recruiting?

NCT04363632 is currently completed. Last updated 1 July 2020.

Last reviewed 2020-07-01 · How we verify

NCT04363632: ONCOVID-19

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prospective Analysis of Morbi-mortality of Patients With Cancers in Active Phase of Treatment Suspected or Diagnosed of a SARS-CoV-2 Infection

Completed Last updated 1 July 2020

What this trial tests

trial in Sars-CoV2 in 1,231 participants. Completed in 30 June 2020.

Timeline

2 April 2020

Primary endpoint
30 June 2020

30 June 2020

Quick facts

Lead sponsor	Centre Leon Berard
Status	Completed
Study type	OBSERVATIONAL
Enrollment	1,231
Start date	2 April 2020
Primary completion	30 June 2020
Estimated completion	30 June 2020
Sites	18 locations across France

Conditions studied

Sars-CoV2 — all drugs for Sars-CoV2 →
Cancer — all drugs for Cancer →

Sponsor

Centre Leon Berard — full company profile →

Who can join

Eligibility, any sex, with Sars-CoV2 or Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

National multicentre epidemiological study to describe retrospectively and prospectively the clinical outcomes of patients with a suspected coronavirus infection (either confirmed or not) while receiving a medical treatment for the underlying cancer

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

High mortality rate in cancer patients with symptoms of COVID-19 with or without detectable SARS-COV-2 on RT-PCR.
Assaad S, Avrillon V, Fournier ML, Mastroianni B, et al · · 2020 · cited 93× · PMID 32540204 · DOI 10.1016/j.ejca.2020.05.028
Cancer Management during COVID-19 Pandemic: Is Immune Checkpoint Inhibitors-Based Immunotherapy Harmful or Beneficial?
Vivarelli S, Falzone L, Grillo CM, Scandurra G, et al · · 2020 · cited 63× · PMID 32785162 · DOI 10.3390/cancers12082237
Mortality of patients with solid and haematological cancers presenting with symptoms of COVID-19 with vs without detectable SARS-COV-2: a French nationwide prospective cohort study.
Assaad S, Zrounba P, Cropet C, ONCOVID-19 study Consortium, et al · · 2021 · cited 20× · PMID 34135471 · DOI 10.1038/s41416-021-01452-4
Mortality of Patients with Cancer Presenting with Symptoms of COVID-19 With vs Without Detectable SARS-CoV-2: A Nationwide Prospective Cohort Study
Assaad S, Zrounba P, Cropet C, Faucher C, et al · · 2020 · DOI 10.2139/ssrn.3706770

Verify or expand the search:

Other recruiting trials for Sars-CoV2

Currently open trials in the same condition.

NCT04466683 — Low-Dose Radiotherapy For Patients With SARS-COV-2 (COVID-19) Pneumonia · Phase 2 · active not recruiting
NCT04433364 — COPE - COVID-19 in Pregnancy and Early Childhood · active not recruiting
NCT04363853 — Tocilizumab Treatment in Patients With COVID-19 · Phase 2 · active not recruiting
NCT04424992 — The Natural History of Hospitalized COVID-19 Patients · recruiting

Other Centre Leon Berard trials

Trials by the same sponsor.

NCT07499921 — Clinical and BIOgical Analyses of RECtal Tumors · NA · not yet recruiting
NCT07515274 — Evaluation of the Effects of Equicoaching on Social Reintegration Among Young Adults Who Have Been Treated for Cancer · NA · not yet recruiting
NCT07243483 — Study of the Relationship Between the Pharmacokinetics (PK) and Pharmacodynamics of Venetoclax in Patients With Acute My · NA · recruiting
NCT07334990 — Impact of a Hypnotic Recording on Artifacts in 4D CT in the Context of Stereotactic Body Radiation Therapy for Lung Canc · NA · not yet recruiting
NCT07414719 — Impact of an HPV Primary Prevention Intervention on HPV Vaccination Rates Among Adolescents in the AuRA Region. · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04363632 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Centre Leon Berard
Last refreshed: 1 July 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04363632.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing